Modality
Bispecific Ab
MOA
TROP-2 ADC
Target
CFTR
Pathway
Amyloid
SMAMMHuntington's
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
Jun 2020
→ Jan 2026
Phase 2Current
NCT03608738
1,179 pts·SMA
2020-06→2026-01·Active
1,179 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-093mo agoPh2 Data· SMA
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2
Active
Catalysts
Ph2 Data
2026-01-09 · 3mo ago
SMA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03608738 | Phase 2 | SMA | Active | 1179 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |